The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
about
The 2014–2015 Ebola outbreak in West Africa: Hands OnA Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary ReportReplicon RNA Viral Vectors as VaccinesBolstering community cooperation in Ebola resurgence protocols: combining field blood draw and point-of-care diagnosisA review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus[Overview of the Ebola vaccines in pre-clinical and clinical development].Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection.Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.Ebola vaccine R&D: Filling the knowledge gaps.Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccineArenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous surveySix-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.Immunization in Canada: Update for 2015.Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic AssaysOne-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.Ebola vaccines in clinical trial: The promising candidates.Vaccine platforms to control Lassa fever.Ebola virus disease candidate vaccines under evaluation in clinical trials.Multivalent and Multipathogen Viral Vector Vaccines.An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial.Musculoskeletal manifestations of Ebola virus.Ebola virus vaccines - reality or fiction?Chikungunya Virus Vaccines: Viral Vector-Based Approaches.Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4Open-label phase I clinical trial of Ad5-EBOV in Africans in China.Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings.Novel viral vectors in infectious diseases.Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.Statistics and logistics: Design of Ebola vaccine trials in West Africa.Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.Ebola virus encodes a miR-155 analog to regulate importin-α5 expression.Therapeutics Against Filovirus Infection.
P2860
Q24049114-8F9E5FA5-C833-4712-8177-67EAE840EFD0Q24289295-E5387A53-CB5D-45C5-A77A-03803F4D0041Q28076639-8B2FE5C5-A2B8-4EB9-936D-F4A088A2B69EQ28950587-9CCF373D-A4EB-40D4-81CE-84CABAA1B387Q29994671-49CDE8AF-FFE7-4B90-8FDA-B7D1597B5451Q30235073-2D663189-0725-4ACA-9F2C-438D9F7CC86AQ30245207-F38D3BFB-32B8-4581-8C31-603D0E5B7159Q33681247-9D153E0B-578C-4668-921A-CF4A800400B2Q33758034-407BA584-2E8A-4765-8F34-17649CB18FB6Q33818337-7FB02212-8E42-4AF3-AEB2-1E3635233E19Q33837161-1CEB9083-3CC8-4C0A-A104-82EC1C5FF4EAQ34504883-771EB6AF-B22A-4D4C-B2BB-3DB245AD3487Q34531417-52BABBC4-E660-4777-99B0-43D98EBF61A0Q35847032-64D32AB5-A194-49D0-8D1F-B34BD8908261Q36300818-D1E4694D-78AF-45A1-9AF3-832E72AE834BQ36382902-4593D334-820D-4722-AF16-0F5450C032E3Q36728581-AC83E69E-A332-41CB-88DE-55427E3A8FEDQ36748120-A9BD58FD-9DDF-4EA1-A648-35F8290A34A4Q37560824-0B5637E6-838D-49C1-A149-6E507E81DC8EQ37713766-786874F1-D8D5-46AF-A97F-6E26C7FBD1D4Q38674025-4BE87747-8EED-4B32-8BAF-19F864CBB507Q38730996-175BE709-82EB-4677-8097-3B0A4AD0EFCAQ38808678-BFE8FB97-14E6-412E-9F6A-3A7A021836B3Q38823264-28FED36C-6746-4A0C-800C-D5FF625EB2E8Q38830109-B93AA7B6-5C40-434D-AC0A-7B24BD14B3AFQ38830323-5E42BCD2-CA7C-4F74-BBA8-A2A111EB35BFQ38834286-0DD09A2D-83FC-4AF8-A7DF-8B50A5E06AA0Q38865003-D06ECBEE-875A-4740-860D-5F4B5E02EDB2Q38873143-C5EED96E-D26D-4286-B0E0-CD6484C842F3Q38881265-CC75ED38-84F4-4BD1-A5C0-62AE7D78B6FEQ39128566-AB4B862B-3DE7-4D14-8A28-9809369BA941Q39157055-9F395777-73E4-41A0-A25F-418BFB860DCBQ40048316-4EC9FC11-47AA-4922-8819-D2BA3581E752Q40053102-0835FA02-0367-4E54-B0CD-D7C37B08CA8EQ40059020-7DDF5E8B-E681-4CE9-988C-9C9C35689FFCQ40093846-DA5ECA82-473B-496A-8B59-3A7FC5D77855Q40107069-8C50E490-78BE-42EF-84BB-D5947A6C3617Q40108305-F1324D5F-149D-4E88-99ED-3D1F50C475EDQ40109156-959969E2-B9D4-4F04-A555-3C057E9E3D86Q40144389-0C6961D8-1C9F-4BC9-90C0-0592807B64C0
P2860
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The effect of dose on the safe ...... bo-controlled phase 1/2 trial.
@en
type
label
The effect of dose on the safe ...... bo-controlled phase 1/2 trial.
@en
prefLabel
The effect of dose on the safe ...... bo-controlled phase 1/2 trial.
@en
P2093
P50
P921
P1476
The effect of dose on the safe ...... bo-controlled phase 1/2 trial.
@en
P2093
Alain Matthey
Angela Huttner
Axel Finckh
Barbara Lemaître
Christophe Combescure
Claire-Anne Siegrist
Floriane Auderset
Gürkan Kaya
Jules Desmeules
Julie-Anne Dayer
P304
P356
10.1016/S1473-3099(15)00154-1
P577
2015-08-03T00:00:00Z